JP2006525782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525782A5 JP2006525782A5 JP2004556543A JP2004556543A JP2006525782A5 JP 2006525782 A5 JP2006525782 A5 JP 2006525782A5 JP 2004556543 A JP2004556543 A JP 2004556543A JP 2004556543 A JP2004556543 A JP 2004556543A JP 2006525782 A5 JP2006525782 A5 JP 2006525782A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- disease
- acid molecule
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 150000007523 nucleic acids Chemical class 0.000 claims 38
- 108020004707 nucleic acids Proteins 0.000 claims 36
- 102000039446 nucleic acids Human genes 0.000 claims 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 31
- 201000010099 disease Diseases 0.000 claims 28
- 238000000034 method Methods 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000003446 ligand Substances 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 10
- 230000014509 gene expression Effects 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 10
- 102000018997 Growth Hormone Human genes 0.000 claims 8
- 108010051696 Growth Hormone Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000000122 growth hormone Substances 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 6
- 239000013068 control sample Substances 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 239000002853 nucleic acid probe Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims 3
- 239000013610 patient sample Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 206010061452 Complication of pregnancy Diseases 0.000 claims 2
- 208000012239 Developmental disease Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 2
- 201000007131 Placental site trophoblastic tumor Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010062282 Silver-Russell syndrome Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 238000009739 binding Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 2
- 208000037824 growth disorder Diseases 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000010916 pituitary tumor Diseases 0.000 claims 2
- 208000012113 pregnancy disease Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000001850 reproductive effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 1
- 208000033054 Cushing disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000031018 biological processes and functions Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0228441.2A GB0228441D0 (en) | 2002-12-05 | 2002-12-05 | Splice variant |
| PCT/GB2003/005295 WO2004050703A1 (en) | 2002-12-05 | 2003-12-05 | Splice variant of the human pituitary growth hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006525782A JP2006525782A (ja) | 2006-11-16 |
| JP2006525782A5 true JP2006525782A5 (enExample) | 2007-01-25 |
Family
ID=9949159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004556543A Pending JP2006525782A (ja) | 2002-12-05 | 2003-12-05 | ヒト下垂体成長ホルモンのスプライスバリアント |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7531508B2 (enExample) |
| EP (1) | EP1569961B1 (enExample) |
| JP (1) | JP2006525782A (enExample) |
| AT (1) | ATE456576T1 (enExample) |
| AU (1) | AU2003285589B2 (enExample) |
| CA (1) | CA2507631A1 (enExample) |
| DE (1) | DE60331166D1 (enExample) |
| DK (1) | DK1569961T3 (enExample) |
| ES (1) | ES2338317T3 (enExample) |
| GB (1) | GB0228441D0 (enExample) |
| NO (1) | NO20052525L (enExample) |
| PT (1) | PT1569961E (enExample) |
| WO (1) | WO2004050703A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140087964A1 (en) * | 2012-09-24 | 2014-03-27 | University Of Virginia Patent Foundation | Compositions and methods for detecting aberrant regulation, expression, and levels of hgh |
| CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| FR2786104B1 (fr) * | 1998-11-25 | 2002-12-27 | Centre Nat Rech Scient | Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques |
-
2002
- 2002-12-05 GB GBGB0228441.2A patent/GB0228441D0/en not_active Ceased
-
2003
- 2003-12-05 DE DE60331166T patent/DE60331166D1/de not_active Expired - Lifetime
- 2003-12-05 DK DK03778588.8T patent/DK1569961T3/da active
- 2003-12-05 EP EP03778588A patent/EP1569961B1/en not_active Expired - Lifetime
- 2003-12-05 US US10/537,142 patent/US7531508B2/en not_active Expired - Fee Related
- 2003-12-05 CA CA002507631A patent/CA2507631A1/en not_active Abandoned
- 2003-12-05 JP JP2004556543A patent/JP2006525782A/ja active Pending
- 2003-12-05 ES ES03778588T patent/ES2338317T3/es not_active Expired - Lifetime
- 2003-12-05 AT AT03778588T patent/ATE456576T1/de active
- 2003-12-05 AU AU2003285589A patent/AU2003285589B2/en not_active Ceased
- 2003-12-05 PT PT03778588T patent/PT1569961E/pt unknown
- 2003-12-05 WO PCT/GB2003/005295 patent/WO2004050703A1/en not_active Ceased
-
2005
- 2005-05-26 NO NO20052525A patent/NO20052525L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6696908B2 (ja) | 肺腺癌の治療方法 | |
| JP2010063458A5 (enExample) | ||
| JP2007537197A5 (enExample) | ||
| CN104619841A (zh) | Cep55基因与ret基因的融合基因 | |
| KR20160138494A (ko) | Fgfr 융합물 | |
| JP2010246558A (ja) | 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法 | |
| US8362224B2 (en) | Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases | |
| JP2014503180A5 (enExample) | ||
| CN105190313B (zh) | 与wnt抑制剂相关的标记物 | |
| JP2008537546A5 (enExample) | ||
| JP2008508861A5 (enExample) | ||
| WO2015017529A2 (en) | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules | |
| JP2002517244A (ja) | 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物 | |
| WO2006014999A2 (en) | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease | |
| JP2013503644A5 (enExample) | ||
| JP4629873B2 (ja) | 単球由来核酸および関連する組成物ならびに方法 | |
| JP2006525782A5 (enExample) | ||
| JP2004187620A (ja) | 腎疾患の疾患マーカーおよびその利用 | |
| JPH1192401A (ja) | ヒト血清グルココルチコイドにより調節されるキナーゼ、慢性腎不全に対する標的 | |
| JP2003510053A (ja) | ヘパラナーゼ蛋白質ファミリーの１種、ヘパラナーゼ−２ | |
| JP2003526322A (ja) | 分泌型システインリッチタンパク質−６（ｓｃｒｐ−６） | |
| WO2006014903A2 (en) | Compositions and methods of use for adam12 antagonists in treating disease | |
| JP2002518016A5 (enExample) | ||
| JP2006526384A5 (enExample) | ||
| JP2006526385A5 (enExample) |